LoginRegister
    Zydus Cadila gets tentative USFDA nod for arthritis drug ApremilastZydus Cadila gets tentative USFDA nod for arthritis drug Apremilast
    Unichem Labs receives US regulatory nod for generic version of Buspar tabletsUnichem Labs receives US regulatory nod for generic version of Buspar tablets
    Bristol Myers Squibb gets FTC okay for acquiring CelgeneBristol Myers Squibb gets FTC okay for acquiring Celgene
    JnJ directed to pay USD 465 million for fueling opioid epidemic via deceptive marketing of painkillersJnJ directed to pay USD 465 million for fueling opioid epidemic via deceptive marketing of...
    Novartis sets out new strategy to provide medicines to more patients in sub-Saharan AfricaNovartis sets out new strategy to provide medicines to more patients in sub-Saharan Africa
    NPPA fixes retail price of 12 combo drugs including Aspirin, Atorvastatin, Metformin; DetailsNPPA fixes retail price of 12 combo drugs including Aspirin, Atorvastatin, Metformin; Details
    Mylan Andhra plant gets USFDA warning over Valsartan manufacturing violationsMylan Andhra plant gets USFDA warning over Valsartan manufacturing violations
    Novartis forecast USFDA approved sickle-cell drug Adakveo annual sales to top USD 1 billionNovartis forecast USFDA approved sickle-cell drug Adakveo annual sales to top USD 1 billion
    Divis Labs gets no USFDA observations for Unit-I Telangana facilityDivis Labs gets no USFDA observations for Unit-I Telangana facility
    Agile birth control patch Twirla USFDA review delayed by 3 months, shares slideAgile birth control patch Twirla USFDA review delayed by 3 months, shares slide
    BeiGene gets USFDA approval for lymphoma drug BrukinsaBeiGene gets USFDA approval for lymphoma drug Brukinsa
    Expanding use of Amarin heart drug Vascepa unanimously backed by USFDA panelExpanding use of Amarin heart drug Vascepa unanimously backed by USFDA panel
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X